Elkis, Helio and Buckley, Peter F. 2016. Treatment-Resistant Schizophrenia. Psychiatric Clinics of North America, Vol. 39, Issue. 2, p. 239.
Takeuchi, H. Powell, V. Geisler, S. DeSanti, M. Fervaha, G. Agid, O. Kane, J. M. and Remington, G. 2016. Clozapine administration in clinical practice: once-daily versus divided dosing. Acta Psychiatrica Scandinavica, Vol. 134, Issue. 3, p. 234.
Kahn, René S. Sommer, Iris E. Murray, Robin M. Meyer-Lindenberg, Andreas Weinberger, Daniel R. Cannon, Tyrone D. O'Donovan, Michael Correll, Christoph U. Kane, John M. van Os, Jim and Insel, Thomas R. 2015. Schizophrenia. Nature Reviews Disease Primers, p. 15067.
Kruse, Gregory Wong, Bruce J. O. Duh, Mei Sheng Lefebvre, Patrick Lafeuille, Marie-Hélène and Fastenau, John M. 2015. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. PharmacoEconomics, Vol. 33, Issue. 10, p. 1049.
López-Muñoz, Francisco Sanz-Fuentenebro, Javier Rubio, Gabriel García-García, Pilar and Álamo, Cecilio 2015. Quo Vadis Clozapine? A Bibliometric Study of 45 Years of Research in International Context. International Journal of Molecular Sciences, Vol. 16, Issue. 9, p. 23012.
Manfra, Ornella Van Craenenbroeck, Kathleen Skieterska, Kamila Frimurer, Thomas Schwartz, Thue W. Levy, Finn Olav and Andressen, Kjetil Wessel 2015. Downregulation of 5-HT7Serotonin Receptors by the Atypical Antipsychotics Clozapine and Olanzapine. Role of Motifs in the C-Terminal Domain and Interaction with GASP-1. ACS Chemical Neuroscience, Vol. 6, Issue. 7, p. 1206.
Razzouk, Denise Kayo, Monica Sousa, Aglaé Gregorio, Guilherme Cogo-Moreira, Hugo Cardoso, Andrea Alves Mari, Jair de Jesus and Stewart, Robert 2015. The Impact of Antipsychotic Polytherapy Costs in the Public Health Care in Sao Paulo, Brazil. PLOS ONE, Vol. 10, Issue. 4, p. e0124791.
Carbon, Maren and Correll, Christoph U. 2014. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectrums, Vol. 19, Issue. S1, p. 35.
Lyseng-Williamson, Katherine A. 2014. Clozapine oral suspension (Versacloz™): a guide to its use in the USA. Drugs & Therapy Perspectives, Vol. 30, Issue. 6, p. 193.
Selent, Jana Marti-Solano, Maria Rodríguez, Javier Atanes, Patricio Brea, José Castro, Marian Sanz, Ferran Loza, M. Isabel and Pastor, Manuel 2014. Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles. European Journal of Medicinal Chemistry, Vol. 77, p. 91.
Warnez, Stephanie and Alessi-Severini, Silvia 2014. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry, Vol. 14, Issue. 1,
Woodward, Todd S. Jung, Kwanghee Smith, Geoffrey N. Hwang, Heungsun Barr, Alasdair M. Procyshyn, Ric M. Flynn, Sean W. van der Gaag, Mark and Honer, William G. 2014. Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. European Archives of Psychiatry and Clinical Neuroscience, Vol. 264, Issue. 8, p. 673.
Lyseng-Williamson, Katherine A. 2013. Clozapine: a guide to its use in patients with schizophrenia who are unresponsive to or intolerant of other antipsychotic agents. Drugs & Therapy Perspectives, Vol. 29, Issue. 6, p. 161.
Clozapine is considered the gold standard for the treatment of patients with treatment-resistant schizophrenia (TRS); however, randomized controlled trials (RCT) of olanzapine showed efficacy similar to clozapine in patients with TRS.
A systematic review was conducted comparing clozapine with olanzapine in patients with TRS. Meta-analyses were performed for single outcome measures. Response to treatment was measured by the percentage of responders, or mean change or endpoint values of psychotic symptoms scales. Effect sizes were shown as relative risks (RR), or standardized mean differences, with 95% confidence intervals.
Seven RCT were included, comprising 648 patients. Five meta-analyses were performed. Olanzapine and clozapine had similar effects on dropout rates (RR = 0.93, CI95% = 0.77–1.12), PANSS total endpoints (SMD = 0.21, CI95% = –0.04–0.46), and PANSS total mean changes (SMD = 0.08, CI95% = –0.01–0.027). Clozapine was superior to olanzapine for PANSS positive (SMD = 0.51, CI95% = 0.17–0.86) and negative (SMD = 0.50, CI95% = 0.16–0.85) subscales. There was a trend toward high doses of olanzapine producing higher effect sizes for this drug.
The results of this study suggest that clozapine is significantly more efficacious than olanzapine in improving positive and negative symptoms in TRS patients.
The authors would like to thank Dr. Carlos B. Pereira, Dr. Ricardo Moreno, and Dr. Orestes Forlenza for their valuable critical comments and suggestions for the manuscript, and also Carolina Rehem, for her library assistance.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.